CD4 and tuberculosis: More recently, the STAMP trial, which assessed patient outcomes using a concurrent LAM and Xpert diagnostic strategy, demonstrated significantly reduced mortality (7.1%) in patients with CD4 counts of <100 cells/μl and detected more TB cases compared to Xpert alone (21.9% versus 14.9%; P < 0.001) (15).